October 25, 2022
EPS Holdings, Inc.
News release

Notice Regarding Corporate Restructuring
EPS Holdings, Inc. (Head Office: Shinjuku-ku, Tokyo; Representative Director: Hao Yan;hereinafter “the Company”) hereby announces that it has decided to make its subsidiary EPPharmaLine Co., Ltd. (Head Office: Toshima-ku, Tokyo; President & Representative Director:Kanami Ikeda; hereinafter “EP-PharmaLine”) a subsidiary of its subsidiary EPNextS Co., Ltd. (HeadOffice: Shinjuku-ku, Tokyo; Representative Director: Tatsuma Nagaoka; hereinafter “EPNextS”), byway of the share delivery method.
１．
Background and Process of Making EP-PharmaLine a Subsidiary of EPNextSAs a solutions provider that contributes to the development of the healthcare industry, theCompany possesses EP-PharmaLine, which conducts sales and marketing activities mainly forpharmaceutical companies as a CSO*3 business under its umbrella, in addition to EPS Corporation(“EPS”), which handles the CRO*1 business, and EP-SOGO Co., Ltd. (“EP-SOGO”), which handles
the SMO*2 business. The Company positions these three as core businesses, and has worked toimprove services and expand its business matched to customer needs, by capitalizing on
collaboration in the Group as well as the know-how and product development capabilities of otherrelated businesses in the Group.
Last year, the Company conducted a management buyout before going on to outline its SHINYO
medium-term management plan, and is now focused on finding and establishing new customer
solutions and revenue models. Under these initiatives, in order to ensure flexible strategic decisionmaking that takes into account overall optimization of the Group, the Company established EPNextSin October as an intermediate holding company to manage these three core businesses, and has
already made EPS of the CRO business and EP-SOGO of the SMO business into subsidiaries ofEPNextS. (See “Establishment of Intermediate Holding Company and Corporate Restructuring,”
issued August 26, 2022, for more details)
The Company has now decided to deliver all shares it holds of EP-PharmaLine, which conducts
the CSO business, to EPNextS, and shift it from being a subsidiary of the Company to a subsidiary ofEPNextS. This concludes the series of corporate restructuring efforts related to core businesses.
However, all we see now is the framework that has only just been formed. Going forward, theintermediate holding company will play a central role in guidance, support, and management foreffective utilization of the management resources of the three core businesses it will manage, andtheir subsidiaries, and for the companies’ operational management and strategy development. It will
also work to maximize corporate value by building a competitive business structure, which will
include strengthening risk management and governance.
Relationships between Companies(Percentages are ownership stakes)
２．

Overview of Entities Involved in Share Delivery
Share delivery parent company

Share delivery subsidiary

NameEPNextS Co., Ltd.

EP-PharmaLine Co., Ltd.

Address

2-1 Tsukudohachimancho,

3-27-12 Nishi-Ikebukuro, Toshima-Shinjuku-ku, Tokyoku, Tokyo

Representative Director

Tatsuma NAGAOKA

Kanami IKEDA

Business area

Making management strategy forDI (drug information) and other callsubsidiaries, research on newcenter services, related BPO

services, M&A strategy execution toservices, and medical device

help raise the added value ofsupport services

subsidiaries' businesses, andrelated activities
Capital

100 million yen

100 million yen

Main shareholder andEPS Holdings, Inc., 100%

EPNextS Co., Ltd. 51%

ownership stakeSUZUKEN CO., LTD. 49%

Establishment

October 4, 2022

Share delivery date

October 25, 2022

November 4, 1997

*1: Contract research organization*2: Site management organization*3: Contract sales organization

Contact: EPS Holdings, Inc.
Corporate Communication OfficeE-mail: pr@eps.co.jp